Figure 5.
Anti-tumor efficacy of MSLN-CAR-T cells against ovarian cancer in vivo
(A) Schema of the experimental events and nodes. In this process, model mice were injected with 1 × 106 OC cells SKOV3. 7 days after injection, 8 mice were randomly divided into 2 groups (n = 4): 2.5 × 106 MSLN-CAR-T cells-treated group and control-T cells-treated group. (B and C) The tumor size (B) and mice weight (C) variation with MSLN-CAR-T cells, control T cells, or PBS injection among the 35 days.(D) Size of SKOV3 CDX tumor mass differed in MSLN-CAR-T cells, control T cells or PBS treated mice. (n = 4, mean ± SEM; p > 0.05, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).